Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a…
Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by online advertisements. Please support us by disabling your Ad Blocker.
